CompanyProfilev2Financials
Actions
Jump To:
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Financials
- FINANCIAL INFORMATION
- FINANCIAL STATEMENTS AND REPORTS
- Annually
- Quarterly
| Balance Sheet | 2023-12-31 | |||
|---|---|---|---|---|
| Total Assets | 1,654,166 | - | - | - |
| Total Liabilities | 249,837 | - | - | - |
| Total Shareholders Equity (After Deducting the Minority Equity) | 1,404,329 | - | - | - |
| Total Liabilities and Shareholders Equity | 1,654,166 | - | - | - |
| Statement of Income | 2023-12-31 | |||
| Total Revenue (Sales/Operating) | 1,100,819 | - | - | - |
| Net Profit (Loss) before Zakat and Tax | 315,799 | - | - | - |
| Zakat and Income Tax | -23,399 | - | - | - |
| Net Profit (Loss) after Zakat and Tax | 292,400 | - | - | - |
| Total Comprehensive Income | 258,066 | - | - | - |
| Profit (Loss) per Share | 4.18 | - | - | - |
| Cash Flows | 2023-12-31 | |||
| Net Cash From Operating Activities | 296,028 | - | - | - |
| Net Cash From Investing Activities | -77,442 | - | - | - |
| Net Cash From Financing Activities | -70,347 | - | - | - |
| Cash and Cash Equivalents, Beginning of the Period | 141,182 | - | - | - |
| Cash and Cash Equivalents, End of the Period | 284,277 | - | - | - |
| All Figures in | Thousands | |||
| All Currency In | SAR | |||
| Last Update Date | 2024-04-01 |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
| Balance Sheet | 2024-03-31 | 2023-09-30 | ||
|---|---|---|---|---|
| Total Assets | 1,760,896.94 | 1,658,857 | ||
| Total Liabilities | 299,401.64 | 297,559 | ||
| Total Shareholders Equity (After Deducting the Minority Equity) | 1,461,495.3 | 1,361,298 | ||
| Total Liabilities and Shareholders Equity | 1,760,896.94 | 1,658,857 | ||
| Statement of Income | 2024-03-31 | 2023-09-30 | ||
| Total Revenue (Sales/Operating) | 385,461.64 | 292,613 | ||
| Net Profit (Loss) before Zakat and Tax | 112,733.14 | 83,858 | ||
| Zakat and Income Tax | -9,763.75 | -6,611 | ||
| Net Profit (Loss) after Zakat and Tax | 102,969.4 | 77,247 | ||
| Total Comprehensive Income | 57,166.33 | 76,433 | ||
| Profit (Loss) per Share | 1.47 | 1.1 | ||
| Cash Flows | 2024-03-31 | 2023-09-30 | ||
| Net Cash From Operating Activities | -46,896.61 | 95,843 | ||
| Net Cash From Investing Activities | -21,324.79 | -68,686 | ||
| Net Cash From Financing Activities | -234.02 | -70,263 | ||
| Cash and Cash Equivalents, Beginning of the Period | 284,276.77 | 141,182 | ||
| Cash and Cash Equivalents, End of the Period | 210,477.38 | 93,191 | ||
| All Figures in | Thousands | Thousands | ||
| All Currency In | SAR | SAR | ||
| Last Update Date | 2024-05-19 | 2023-11-12 |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
Display Previous Periods
Jump To:
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Jump To:
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Jump To:
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Company Profile
Company overview
The Company is primarily focused on developing, manufacturing, and distributing a wide range of generic pharmaceuticals, cosmetics, and consumer healthcare products. Its products are supplied and marketed in over 36 countries spanning across the GCC, Levant, North Africa, and other regions, the company is committed to providing high-quality products to its customers. Its extensive portfolio of offerings and its widespread distribution network make it a leading player in the industry
Company History
Jamjoom Pharmaceuticals Factory Company was established as a branch of Abdullatif Mohammed Salah Jamjoom and Brothers Company under commercial registration no. 4030106218 dated 16/04/1415H (corresponding to 22/09/1994G) issued in Jeddah, KSA. On 12/09/1425H (corresponding to 26/10/2004G), the branch of Abdullatif Mohammed Salah Jamjoom and Brothers Company was converted into a limited liability company under the name of Jamjoom Pharmaceuticals Factory Company Limited under commercial registration no. 4030154596 dated 18/02/1426H (corresponding to 28/03/2005G) with a capital of twenty million Saudi Riyals (SAR 20,000,000). On 17/11/1428H (corresponding to 27/11/2007G), the General Assembly approved an increase of the Company''s capital from twenty million Saudi Riyals (SAR 20,000,000) to sixty million Saudi Riyals (SAR 60,000,000) divided into sixty thousand (60,000) cash shares of equal value of one thousand Saudi Riyals (SAR 1,000) per share, through the capitalization of forty million Saudi Riyals (SAR 40,000,000) from the retained earnings account. On 09/06/1433H (corresponding to 30/04/2012G), the General Assembly approved an increase of the Company''s capital from sixty million Saudi Riyals (SAR 60,000,000) to one hundred million Saudi Riyals (SAR 100,000,000) , divided into one hundred thousand (100,000) cash shares of equal value of one thousand Saudi Riyals (SAR 1,000) per share, through the capitalization of forty million Saudi Riyals (SAR 40,000,000) from the retained earnings account. On 09/11/1434H, (corresponding to 21/01/2013G), the Company was converted from a limited liability company to a (closed) joint-stock company pursuant to a ministerial resolution no. 202/s, dated 19/08/1435H (corresponding to 17/06/2014G) approving the publication of the Company''s conversion. Upon conversion, the Company''s share capital was one hundred million Saudi Riyals (SAR 100,000,000), divided into ten million (10,000,000) Shares with a fully paid-up nominal value of SAR 10 per share. On 18/12/1443H (corresponding to 17/07/2022G), the General Assembly approved an increase of the Company''s capital from one hundred million Saudi Riyals (SAR 100,000,000) to seven hundred million Saudi Riyals (SAR 700,000,000), divided into seventy million (70,000,000) Shares with a fully-paid up nominal value of SAR 10 consisting of ten million ordinary shares paid in-kind and sixty million (60,000,000) ordinary shares paid in cash, per Share through the capitalization of six hundred million Saudi Riyals (SAR 600,000,000) from the retained earnings account.
Company Bylaws
Click here
Equity Profile
- Authorized Capital (SAR) 700,000,000
- Issued Shares 70,000,000
- Paid Capital (SAR) 700,000,000
- Par Value/Share 10
- Paid Up Value/Share 10
Last Update :2023-06-20
Investment limits
There are no investment limits on the company's shares as per the amended Rules for Qualified Foreign Financial Institutions Investment in Listed Securities and Instructions for the Foreign Strategic Investors Ownership in Listed Companies based on Company's bylaw and the issued Instructions by related regulators and supervisory authorities.
- Company Details
- BOARD OF DIRECTORS AND SENIOR EXECUTIVES INFORMATION
-
Date Established
1994/09/22
-
Financial Year End
31/12
-
Listing Date
2023/06/20
-
External Auditors
[KPMG Professional Services]
-
ISIN CODE
SA15QGU1UNH6
-
Number of Employees
1241
-
Chairman
Mahmoud Yousuf Mohammed Salah Jamjoom
Non - ExecutiveMahmoud Yousuf Mohammed Salah Jamjoom
-
BD Session Start
2022-06-19
Designation
Chairman
-
BD Session End
2025-06-18
Classification
Non - Executive
-
Qualification
Bachelor's Degree in Science from Michigan State University, in East Lansing Michigan, United States, 1985G.
Companies Membership
-
Memebrship Name
Jamjoom Pharmaceuticals Factory Company
Start Date
2021-01-01
Memebrship Character
Member of the Executive Committee at the Company
End Date
2024-01-01
-
Memebrship Name
Jamjoom New Medical Care
Start Date
2019-01-01
Memebrship Character
Member of the Board of Directors
End Date
-
-
-
Board of Directors
Ahmed Yousuf Mohammed Salah Jamjoom Executive
Ahmed Yousuf Mohammed Salah Jamjoom
-
BD Session Start
2022-06-19
Designation
Board of Directors
-
BD Session End
2025-06-18
Classification
Executive
-
Qualification
Master's degree in pharmacy, from Ibn Sina Medical College, in Jeddah, The Kingdom, 2010G. Mini Master of Business Administration degree in Pharma and Biotech Industry from Management Centre Europe, Brussels, Belgium, 2015. Certificate in Global Management, from the European Institute of Business Administration 'INSEAD', France, Ventenbelau, 2019G.
Companies Membership
-
Memebrship Name
See AlsoHans Petter Midttun on LinkedIn: I’m greatly honoured to have been invited to speak about Security and…Hans Petter Midttun on LinkedIn: Opinion: Dynamic ‘Stalemate’ – Perception Problems From Faulty FocusPan Gulf Marketing Co. Announces the Results of the Extra Ordinary General Assembly’s Meeting Approving Increase ( First Meeting )Company Profile Main MarketJamjoom Pharmaceuticals Factory Company
Start Date
2021-01-01
Memebrship Character
Member of the Executive Committee at the Company
End Date
2024-01-01
-
Memebrship Name
Abdullatif Mohammed Salah Jamjoom and Brothers Company
Start Date
2014-01-01
Memebrship Character
Member of the Board of Directors
End Date
-
-
Memebrship Name
SHIFT Inc.
Start Date
2017-01-01
Memebrship Character
Member of the Board of Directors
End Date
-
-
Memebrship Name
SHIFT Inc.
Start Date
2020-01-01
Memebrship Character
Member of the Audit Committee
End Date
-
-
Memebrship Name
Madinah Newspapers and Printing
Start Date
2017-01-01
Memebrship Character
Member of the Board of Directors
End Date
2022-12-31
Yousuf Mohammed Salah Abdulaziz Jamjoom Non - Executive
Yousuf Mohammed Salah Abdulaziz Jamjoom
-
BD Session Start
2022-06-19
Designation
Board of Directors
-
BD Session End
2025-06-18
Classification
Non - Executive
-
Qualification
Diploma degree in Commerce from the College of Leeds, in Leeds, United Kingdom, 1947G
Companies Membership
-
Memebrship Name
Jamjoom Pharmaceuticals Factory Company
Start Date
2013-12-31
Memebrship Character
Chairman of the Board of Directors
End Date
2022-06-19
-
Memebrship Name
Jamjoom New Medical Care
Start Date
2019-01-01
Memebrship Character
Member of the Board of Directors
End Date
-
-
Memebrship Name
Abdullatif Mohammed Salah Jamjoom and Brothers Company
Start Date
1965-01-01
Memebrship Character
Chairman of the Board of Directors
End Date
2021-12-31
Mohammed Yousuf Mohammed Salah Jamjoom Non - Executive
Mohammed Yousuf Mohammed Salah Jamjoom
-
BD Session Start
2022-06-19
Designation
Board of Directors
-
BD Session End
2025-06-18
Classification
Non - Executive
-
Qualification
Bachelor's degree in Medicine and Surgery from King Abdulaziz University, The Kingdom, 1983G. Fellowship in Orthopaedic Surgery from the Royal College of Physicians of Canada, Ottawa, Canada, 1993G
Companies Membership
-
Memebrship Name
Jamjoom Medicine Store
Start Date
2021-01-01
Memebrship Character
Member of the Executive Committee
End Date
-
-
Memebrship Name
Jamjoom New Medical Care
Start Date
2019-01-01
Memebrship Character
Member of the Board of Directors
End Date
-
Alaa Yousuf Mohammed Salah Jamjoom Non - Executive
Alaa Yousuf Mohammed Salah Jamjoom
-
BD Session Start
See AlsoCompany Profile Nomu Parallel2022-06-19
Designation
Board of Directors
-
BD Session End
2025-06-18
Classification
Non - Executive
-
Qualification
Bachelor's Degree in Computer and Statistics from King Abdulaziz University, in Jeddah, The Kingdom, 2005G. Master's Degree in Executive Business Administration from King Abdulaziz University, in Jeddah, The Kingdom, 2008G
Companies Membership
-
Memebrship Name
Jamjoom Pharmaceuticals Factory Company
Start Date
-
Memebrship Character
Member of the Nomination and Remuneration Committee
End Date
-
Faris Ibrahim Abdullah Al Ghannam Independent
Faris Ibrahim Abdullah Al Ghannam
-
BD Session Start
2022-06-19
Designation
Board of Directors
-
BD Session End
2025-06-18
Classification
Independent
-
Qualification
Bachelor's Degree in Computer Science from Prince Sultan University, The Kingdom, 2005G. Master's Degree in Business Administration from University of Rice, United States, 2011G
Companies Membership
-
Memebrship Name
Jamjoom Pharmaceuticals Factory Company
Start Date
2022-01-01
Memebrship Character
Chairman of the Audit Committee
End Date
-
-
Memebrship Name
Prince Sultan University, The Kingdom
Start Date
2022-01-01
Memebrship Character
Member of the Advisory Committee for the Finance Program
End Date
-
Noor Ahmed Kather Pasha Sheriff Non - Executive
Noor Ahmed Kather Pasha Sheriff
-
BD Session Start
2022-06-19
Designation
Board of Directors
-
BD Session End
2025-06-18
Classification
Non - Executive
-
Qualification
Bachelor's Degree in Science from Bangalore University, India, 1966G. Bachelor's Degree in Law from Bangalore University, India, 1968G
Companies Membership
-
Memebrship Name
Allergan-Primal, India
Start Date
1994-01-01
Memebrship Character
Member of the Board of directors
End Date
1996-12-31
-
Memebrship Name
Hydron International, India
Start Date
1982-01-01
Memebrship Character
Member of the Board of Directors
End Date
1989-12-31
Michel Marcel Jean-Marie Le Bars Independent
Michel Marcel Jean-Marie Le Bars
-
BD Session Start
2022-06-19
Designation
Board of Directors
-
BD Session End
2025-06-18
Classification
Independent
-
Qualification
Certificate in Mechanical Engineering (equivalent to a Master's Degree) from the University of Compiegne for Technology, in Compiegne, France, 1994G. Certificate in Petroleum Engineering (drilling and reservoir management) from ENS Petroleum & Engines at the French Institute of Petroleum, in Rueil-Malmaison, in Paris, France, 1995G. Master Degree in Business Administration from Higher Education School of Business in Paris (HEC), France, 2005G. Certificate in Digital Business Strategy from Massachusetts Institute of Technology, in Cambridge, Massachusetts, United States, 2019G.
Companies Membership
-
Memebrship Name
Jamjoom Pharmaceuticals Factory Company
Start Date
2022-01-01
Memebrship Character
Chairman of the Executive Committee
End Date
-
-
Memebrship Name
Jamjoom Pharmaceuticals Factory Company
Start Date
2022-01-01
Memebrship Character
Chairman of the Nomination and Remuneration
End Date
-
-
Memebrship Name
LeBars Partners GmbH
Start Date
2019-01-01
Memebrship Character
Owner and Managing Director
End Date
-
Georges P. Schorderet Independent
Georges P. Schorderet
-
BD Session Start
2023-07-04
Designation
Board of Directors
-
BD Session End
2025-06-18
Classification
Independent
-
Qualification
Master of Business Administration (MBA), IMI International Management Institute, Geneva, Switzerland, 1983. Swiss Certified Public Accountant and Controller, 1985.
Companies Membership
-
Memebrship Name
SAPIN Saudi Arabian Packaging Company WLL, Dammam, Saudi Arabia
Start Date
2021-01-01
Memebrship Character
Member of the Board of directors
End Date
-
-
Memebrship Name
Sultan Holding, Riyadh, Saudi Arabia
Start Date
2021-01-01
Memebrship Character
Member of the Board of directors
End Date
-
-
Memebrship Name
Helvetican Group AG, 6072 Sachseln, Switzerland
Start Date
2021-04-01
Memebrship Character
Member of the Board of directors
End Date
-
-
Memebrship Name
SBASA - Swiss Business Association Saudi Arabia
Start Date
2021-10-01
Memebrship Character
Chairman
End Date
-
-
Memebrship Name
Global Steel Dust Gulf, Dammam, Saudi Arabia
Start Date
2021-09-01
Memebrship Character
Member of the Board of directors
End Date
-
-
-
Senior Executives
Tarek Youssef Hosni CEO
Tarek Youssef Hosni
-
BD Session Start
-
Designation
Senior Executives
-
BD Session End
-
Classification
CEO
-
Qualification
Bachelor's degree in Pharmacy from Alexandria University, Egypt, 1984G. Master's Degree in Business Administration from Bradford University, United Kingdom, 1997G.
Companies Membership
-
Memebrship Name
Ultra Group Company
Start Date
2022-01-01
Memebrship Character
Member of the Board of Directors
End Date
-
-
Memebrship Name
Jamjoom Pharmaceuticals Factory Company
Start Date
2021-01-01
Memebrship Character
Member of the Executive Committee
End Date
-
Anwer Mohiuddin CFO
-
Anwer Mohiuddin
-
BD Session Start
-
Designation
Senior Executives
-
BD Session End
-
Classification
CFO
-
Qualification
Bachelor's Degree of Commerce from University of Karachi, Pakistan, 1985G. Master's Degree of Economics from University of Karachi, Pakistan, 1989G. Master's Degree of Business Administration with a Major in Marketing form Cardiff University, United Kingdom, 2019G Associate Member of Institute of Cost and Management Accountants of Pakistan (ACMA), Pakistan, 1994.
Investor Relations
Contact Name:
Muhammad Bin Khalid Khan
Company Address:
P.O. Box # 6267, Jeddah-21442, Kingdom of Saudi Arabia
Contact Details:
Telephone:+966 12 614 0099
Fax: +966 12 614 0088
Email: IR@Jamjoompharma.com
Company Website:
| Name Of Subsidiary | Percentage Of Property | Main Business | Location Of Operation | Country Of Operation |
|---|---|---|---|---|
| Al-Jamjoom Pharma for Pharmaceutical Industries | 100.00% | Establishing and operating a factory for the manufacture of human and veterinary medicines, medical preparations, and packaging requirements of all kinds, as well as manufacturing for third parties and by third parties. | Egypt | Egypt |
Add To Watchlist
In your Watchlist
Add To Watchlist
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of these disclosures, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of these disclosures, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.
